Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma

Bone Marrow Transplantation volume 33, pages 629–634 (2004)Cite this article

Summary:

Treatment of cutaneous T-cell and B-cell lymphomas is difficult and relapses are frequent. To evaluate the efficiency of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) on relapsing cutaneous lymphomas, we conducted a retrospective study of 14 patients. We investigated the clinical and histological parameters of the lymphoma, previous treatments to ASCT, short-term complications of ASCT, and occurrence of a relapse. There were 11 males and three females, with a median age of 42 years. Most often, the skin disease was disseminated without extracutaneous involvement. Four patients had a B-cell lymphoma and 10 a T-cell lymphoma. CD30 was negative in 8/10 T-cell lymphomas. Before ASCT, 13 patients had chemosensitive disease; one had refractory disease. The conditioning regimen included TBI in nine cases. No toxic death occurred. Relapse of the lymphoma occurred in eight cases (T-cell lymphoma in seven cases), within 4 months after ASCT in six cases. Relapses were treated with local treatment, interferon or classical chemotherapy. At the end of the study, 11 patients were alive and three patients had died. HDT and ASCT do not benefit patients with T-cell lymphomas. For patients with disseminated relapsing cutaneous B-cell lymphomas, this procedure should be considered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sander CA, Kind P, Kaudewitz P et al. The REAL classification of lymphoid neoplasms: a new perspective for the classification of cutaneous lymphoma. J Cutan Pathol 1997; 24: 329–341.

    CAS  Google Scholar 

  2. Mirza I, Macpherson N, Paproski S et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic and molecular features. J Clin Oncol 2002; 20: 647–655.

    CAS  Google Scholar 

  3. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer. Blood 1997; 1: 354–371.

    Google Scholar 

  4. Knobler RM, Edelson RL . Cutaneous T cell lymphoma. Med Clin North Am 1986; 70: 109–138.

    CAS  Google Scholar 

  5. Kaye FJ, Bunn PA, Steinberg SM et al. A randomised trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New Engl J Med 1989; 321: 1784–1790.

    CAS  Google Scholar 

  6. Burke JS, Hoppe RT, Cibull ML, Dorfman RF . Cutaneous malignant lymphoma, a pathologic study of 50 cases with clinical analysis of 37. Cancer 1981; 47: 300–310.

    CAS  Google Scholar 

  7. Brice P, Cazals D, Mounier N et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Leukemia 1998; 12: 213–219.

    CAS  Google Scholar 

  8. Joly P, Charlotte F, Leibowitch M et al. Cutaneous lymphomas other than mycosis fungoides: follow up study of 52 patients. J Clin Oncol 1991; 9: 1994–2001.

    CAS  Google Scholar 

  9. Bosly A, Coiffier B, Gisselbrecht C et al. Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH84 regimen. J Clin Oncol 1992; 10: 1612–1623.

    Google Scholar 

  10. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    CAS  Google Scholar 

  11. Horning SJ . Natural history of and therapy for the indolent non-Hodgkin's lymphoma. Semin Oncol 1993; 20 (Suppl. 5): 75–88.

    CAS  Google Scholar 

  12. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non Hodgkin's lymphoma. Blood 1991; 77: 2524–2529.

    CAS  Google Scholar 

  13. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262.

    CAS  Google Scholar 

  14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 1999; 17: 1244.

    CAS  PubMed Central  Google Scholar 

  15. Brice P, Marolleau JP, Pautier P et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22: 449–456.

    CAS  Google Scholar 

  16. Gribben JG, Linch DC, Singer CR et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344.

    CAS  Google Scholar 

  17. Marolleau JP, Baccard M, Flageul B et al. High dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995; 131: 574–579.

    CAS  Google Scholar 

  18. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 76–82.

    CAS  PubMed Central  Google Scholar 

  19. Shipp MA . Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk’ disease? Blood 1994; 83: 1165–1173.

    CAS  Google Scholar 

  20. Bigler RD, Crilley P, Micaily B et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7: 133–137.

    CAS  Google Scholar 

  21. Moreau P, LeTortorec S, Mahé MA et al. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma. Bone Marrow Transplant 1994; 14: 775–778.

    CAS  Google Scholar 

  22. Fanin R, Silvestri F, Geromin A et al. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/−radiotherapy) and autologous bone marrow transplantation. Blood 1996; 4: 1243–1248.

    Google Scholar 

  23. Olavarria E, Child F, Woolford A et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624–631.

    CAS  Google Scholar 

  24. Sterling JC, Marcus R, Burrows NP, Roberts SOB . Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 1995; 20: 73–75.

    CAS  Google Scholar 

  25. Ferra C, Servitje O, Petriz L et al. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 1999; 140: 1188–1189.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Saint-Louis Hospital, Paris, Cedex, France

    S Ingen-Housz-Oro, H Bachelez, C Lebbé, L Dubertret & P Morel

  2. Department of Dermatopathology, Saint-Louis Hospital, Paris, Cedex, France

    O Verola

  3. Department of Onco-Haematology, Saint-Louis Hospital, Paris, Cedex, France

    J P Marolleau, C Gisselbrecht & P Brice

  4. Department of Radiotherapy, Saint-Louis Hospital, Paris, Cedex, France

    C Hennequin

Authors
  1. S Ingen-Housz-Oro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Bachelez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Verola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Lebbé
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J P Marolleau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Hennequin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Dubertret
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Morel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Gisselbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Ingen-Housz-Oro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ingen-Housz-Oro, S., Bachelez, H., Verola, O. et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 33, 629–634 (2004). https://doi.org/10.1038/sj.bmt.1704411

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704411

Keywords

This article is cited by

Search

Advanced search

Quick links